Amylyx Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Amylyx Pharmaceuticals's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 135.1% per year. Amylyx Pharmaceuticals's return on equity is 11.4%, and it has net margins of 12.9%.
Key information
-3.6%
Earnings growth rate
37.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 135.1% |
| Return on equity | 11.4% |
| Net Margin | 12.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12
An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans
Dec 19Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct 07Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis
Sep 30Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing
Sep 08Amylyx plunges 28% after FDA briefing documents on ALS drug
Sep 02We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Aug 29Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01
Aug 11Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada
Jul 29Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates
Jul 18Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis
Jul 04Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last
Jun 17We're Keeping An Eye On Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
May 07Amylyx: Crucial Advisory Committee Meet Tomorrow, Approval Chancy
Mar 29Revenue & Expenses BreakdownBeta
How Amylyx Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 381 | 49 | 188 | 0 |
| 30 Sep 23 | 294 | 2 | 177 | 10 |
| 30 Jun 23 | 192 | -73 | 158 | 0 |
| 31 Mar 23 | 94 | -149 | 145 | 2 |
| 31 Dec 22 | 22 | -198 | 127 | 0 |
| 30 Sep 22 | 0 | -184 | 101 | 67 |
| 30 Jun 22 | 0 | -153 | 82 | 0 |
| 31 Mar 22 | 0 | -121 | 59 | 20 |
| 31 Dec 21 | 0 | -88 | 39 | 0 |
| 30 Sep 21 | 1 | -68 | 28 | 0 |
| 31 Dec 20 | 1 | -42 | 15 | 0 |
| 31 Dec 19 | 1 | -14 | 3 | 0 |
Quality Earnings: AMLX has a large one-off gain of $9.9M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: AMLX became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AMLX has become profitable over the past 5 years, growing earnings by -3.6% per year.
Accelerating Growth: AMLX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AMLX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: AMLX's Return on Equity (11.4%) is considered low.